Missing: Oxford Molecular's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Oxford Molecular's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Oxford Molecular News
May 5, 2021
August 9, 20053:00 am Princeton-based Pharmacopeia (Nasdaq: PCOP) today said it has signed an agreement to buy the software unit of England”s Oxford Molecular Group (London: OMG) for $27 million comprising cash and the assumption of certain liabilities. The acquisition is subject to approval by Oxford shareholders and will be accounted for using the purchase method of accounting. On completion of the transaction, Pharmacopeia will integrate Oxford”s bioinformatics and cheminformatics products into its life sciences software business. The acquisition will provide Pharmacopeia with three key assets: an industry leading position in the large and growing field of bioinformatics, a broad line of cheminformatics products that complement Pharmacopeia”s existing chemical database tools from Synopsys Scientific Systems, and a group of more than 120 talented employees. Pharmacopeia bought Synopsys Scientific Systems in February for about $25 million to boost its data-services capabilities. “The acquisition of Oxford Molecular”s software business is strategically very significant for Pharmacopeia,” said Joseph A. Mollica, Pharmacopeia”s CEO. “We believe their bioinformatics products are unmatched in quality and scientific utility. They serve an increasingly important function as efforts continue to sequence and understand the human genome. This acquisition should serve to fuel Pharmacopeia”s continued growth.” Oxford Molecular Group is a worldwide supplier of integrated discovery software and collaborative development services, for use by companies and academic institutions in the fields of pharmaceutical and biotechnology research. Its software business, which generated revenues of $15 million in 1999, designs and markets bioinformatics and cheminformatics products for the pharmaceutical, biotechnology and chemical industries. Pharmacopeia is a leader in enabling science and technology that accelerates drug discovery and chemical development. Pharmacopeia”s drug discovery services segment integrates proprietary small molecule combinatorial chemistry, high-throughput screening and informatics to accelerate its customers” drug discovery efforts. Its software segment, which includes MSI and Synopsys Scientific Systems, develops and commercializes molecular modeling, simulation and informatics software and services. The company employs 550 people and generated 1999 revenues of $104 million.
Oxford Molecular Frequently Asked Questions (FAQ)
Where is Oxford Molecular's headquarters?
Oxford Molecular's headquarters is located at 14940 Northwest Greenbrier Parkway, Beaverton.
What is Oxford Molecular's latest funding round?
Oxford Molecular's latest funding round is Other Investors.
Who are the investors of Oxford Molecular?
Investors of Oxford Molecular include Edelson Technology Partners.
Who are Oxford Molecular's competitors?
Competitors of Oxford Molecular include Pepscan, MolecularMD, IntelligentMDx, CareDx, BioVidria and 12 more.
Compare Oxford Molecular to Competitors
PolyAn Molecular Surface Engineering: fluorescent encoded polymer microspheres (beads), microarray slides and membranes for Pervaporation and organophilic Nanofiltration
Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.
SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.
Intelligent Medical Devices, dba IntelligentMDx, develops and manufactures tests, under regulatory compliance, for a broad range of molecular based systems for use in clinical molecular diagnostics, drug development and applied science applications. Its aim is to translate the needs of the clinician, patient and partners into very specific, highly sensitive, robust clinically impactful tests, thus enabling caregivers worldwide to improve patient care.
BioVidria is commercializing high-sensitivity slides for DNA and protein microarrays. The technology utilizes a patented process to provide high surface area and optical transparency. This aims to offer the customer the ability to detect smaller quantities of mRNA, DNA and antigens.
Sidec Technologies enables visualization of cellular events in 3-D at the molecular level
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.